Tuesday, January 6, 2009

YM Biosciences receives clearance to initiate randomized double-blind clinical trials of Nimotuzumab in lung cancer & brain metastases from lung cance

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER